http://orcid.org/0000-0002-3588-7874
References
- Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct Carcinoma. J Clin Oncol. 2018;JCO1800545. doi:10.1200/JCO.18.00545.
- Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, et al. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget. 2018;9(35687–35704). doi:10.18632/oncotarget.26286
- Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(109–119). doi:10.1056/NEJMoa1113216
- Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 2013;11(307). doi:10.1186/1479-5876-11-307
- Mok MY, Li WL. Do Asian patients have worse lupus? Lupus. 2010;19:1384–1390. doi:10.1177/0961203310375832.
- Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013;6(1). doi:10.1186/1756-8722-6-1.
- Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJY, et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 2017;292(3900–3908). doi:10.1074/jbc.M116.767749
- Shivange G, Urbanek K, Przanowski P, Perry JS, Jones J, Haggart R, Kostka C, Patki T, Stelow E, Petrova Y, et al. A single-agent dual-specificity targeting of FOLR1 and DR5 as an effective strategy for ovarian cancer. Cancer Cell. 2018;34:331–345, E311. doi:10.1016/j.ccell.2018.07.005.
- Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87(21–27). doi:10.1038/sj.bjc.6600347.
- Routy B, Le Chatelier E, Derosa L., Duong CP, Alou MT, Daillère R, Fluckiger A, Messaoudene M., Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(91–97). doi:10.1126/science.aan3706